Centre for Proteomic Research, Biological Sciences, University of Southampton, Southampton, United Kingdom; NIHR Southampton Biomedical Research Centre, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
NIHR Southampton Biomedical Research Centre, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
J Allergy Clin Immunol. 2019 Jul;144(1):70-82. doi: 10.1016/j.jaci.2019.03.013. Epub 2019 Mar 28.
Stratification by eosinophil and neutrophil counts increases our understanding of asthma and helps target therapy, but there is room for improvement in our accuracy in prediction of treatment responses and a need for better understanding of the underlying mechanisms.
We sought to identify molecular subphenotypes of asthma defined by proteomic signatures for improved stratification.
Unbiased label-free quantitative mass spectrometry and topological data analysis were used to analyze the proteomes of sputum supernatants from 246 participants (206 asthmatic patients) as a novel means of asthma stratification. Microarray analysis of sputum cells provided transcriptomics data additionally to inform on underlying mechanisms.
Analysis of the sputum proteome resulted in 10 clusters (ie, proteotypes) based on similarity in proteomic features, representing discrete molecular subphenotypes of asthma. Overlaying granulocyte counts onto the 10 clusters as metadata further defined 3 of these as highly eosinophilic, 3 as highly neutrophilic, and 2 as highly atopic with relatively low granulocytic inflammation. For each of these 3 phenotypes, logistic regression analysis identified candidate protein biomarkers, and matched transcriptomic data pointed to differentially activated underlying mechanisms.
This study provides further stratification of asthma currently classified based on quantification of granulocytic inflammation and provided additional insight into their underlying mechanisms, which could become targets for novel therapies.
通过嗜酸性粒细胞和中性粒细胞计数分层可以提高我们对哮喘的认识,并有助于靶向治疗,但在预测治疗反应的准确性方面仍有改进的空间,需要更好地了解潜在机制。
我们试图通过蛋白质组学特征来确定哮喘的分子亚表型,以进行更好的分层。
使用无偏标签自由定量质谱和拓扑数据分析来分析 246 名参与者(206 名哮喘患者)的痰上清液蛋白质组,作为一种新的哮喘分层方法。痰细胞的微阵列分析提供了转录组学数据,以进一步了解潜在机制。
对痰蛋白质组的分析产生了 10 个聚类(即蛋白质型),基于蛋白质组特征的相似性,代表了哮喘的离散分子亚表型。将粒细胞计数作为元数据叠加到这 10 个聚类上,进一步将其中 3 个定义为高度嗜酸性粒细胞,3 个定义为高度中性粒细胞,2 个定义为高度过敏,粒细胞炎症相对较低。对于这 3 种表型中的每一种,逻辑回归分析都确定了候选蛋白生物标志物,匹配的转录组学数据指出了不同的潜在机制。
本研究提供了基于粒细胞炎症定量的哮喘的进一步分层,并提供了对其潜在机制的更多了解,这些潜在机制可能成为新型治疗方法的靶点。